Statins protect a far wider range of people at risk of myocardial infarct and stroke than previously thought.
They have been found to offer protection among patients with diabetes, arterial disease, those who have previously had a stroke, women as well as men, and both the young and old (70 plus).
Most strikingly, substantial benefits are shown among high-risk patients considered to have levels of total cholesterol below 5 mmol/l (approx. 200 mg/dl), or LDL cholesterol below 3mmol/l (approx. 120mg/dl), as well as those with high cholesterol levels.
A future report by the clinicians will show that simvastatin not only reduces the risk of a first event but also reduces the risk of subsequent events. These are the landmark findings in the Heart Protection Study (HPS), led by Dr Rory Collins and colleagues from the University of Oxford Medical Research Council Clinical Trial Service Unit, Oxford, England, and in collaboration with clinicians with the British Heart Foundation.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!